This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by MacRae, C. A. Articles by Seidman, C. E. Search for Related Content PubMed PubMed Citation Articles by MacRae, C. A. Articles by Seidman, C. E.

Circulation, Vol 89, 33-35, Copyright © 1994 by American Heart Association

ARTICLES

An evaluation of ribonuclease protection assays for the detection of beta-cardiac myosin heavy chain gene mutations

CA MacRae, HC Watkins, JA Jarcho, L Thierfelder, WJ McKenna, JG Seidman and CE Seidman
Department of Genetics, Harvard Medical School, Boston, Mass. 02115.

BACKGROUND: Ribonuclease (RNase) protection has been used to identify beta-cardiac myosin heavy chain (MHC) gene mutations that cause familial hypertrophic cardiomyopathy (FHC). Since more than 10 different mutations within this gene have been demonstrated to cause FHC in unrelated individuals, the genetic diagnosis of this condition will involve screening the beta-MHC gene. The accuracy with which RNase protection identifies such mutations is critical to defining the utility of this methodology in detecting mutations that cause FHC. METHODS AND RESULTS: Twelve unrelated individuals with FHC were selected for further study because their beta-MHC genes had been screened for mutations by use of RNase protection, and no mutation was found. We performed linkage analysis of the families of these 12 probands using polymorphic short tandem repeats within the beta-MHC gene to determine whether FHC was genetically linked to the MHC locus on chromosome 14. FHC was not genetically linked to the MHC locus in 11 families whose beta-cardiac MHC gene did not contain mutations detectable by RNase protection. CONCLUSIONS: We conclude that RNase protection is a sensitive method for screening for mutations within the beta-cardiac MHC gene. Further, mutations in the noncoding regions of the beta-MHC gene and mutations in the alpha-cardiac MHC gene are not a common cause of FHC. Negative RNase protection assays of affected individuals suggest that their FHC is due to mutations at other loci.

This article has been cited by other articles:

				H. MORITA, S.R. DEPALMA, M. ARAD, B. MCDONOUGH, S. BARR, C. DUFFY, B.J. MARON, C.E. SEIDMAN, and J.G. SEIDMAN Molecular Epidemiology of Hypertrophic Cardiomyopathy Cold Spring Harb Symp Quant Biol, January 1, 2002; 67(0): 383 - 388. [Abstract] [PDF]

				H. Watkins, W. J. McKenna, L. Thierfelder, H. J. Suk, R. Anan, A. O'Donoghue, P. Spirito, A. Matsumori, C. S. Moravec, J.G. Seidman, et al. Mutations in the Genes for Cardiac Troponin T and {alpha}-Tropomyosin in Hypertrophic Cardiomyopathy N. Engl. J. Med., April 20, 1995; 332(16): 1058 - 1065. [Abstract] [Full Text] [PDF]